Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Breast Cancer Risk Factors

Further study is needed to assess toremifene for chemoprevention

The scientists initiated "a double-blind, randomized, placebo-controlled pilot study to evaluate the feasibility of chemoprevention with toremifene 60 mg/day in healthy women at high risk for breast cancer. Enrollment in the study was terminated earlier than planned because of slow patient accrual, although 13% of patients continued for 5 years."

"The revised efficacy outcomes were change in bone mineral density (BMD) from baseline at four skeletal sites, plus effects on serum lipids," explained R. Erkkola and colleagues....

• View Other Issues of Women's Health Weekly
  
• View Other NewsRx Publications